• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by STERIS plc (Ireland)

    6/25/25 4:16:24 PM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email
    11-K 1 ste1231202411-kdocument.htm 11-K Document

    Securities and Exchange Commission
    Washington, D. C. 20549
    __________________________________________
    FORM 11-K
      __________________________________________
     
     
    ýAnnual Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934
    For the Twelve Month Period Ended December 31, 2024
    OR
     
    oTransition Report Pursuant to Section 15(d) of The Securities Exchange Act of 1934
    For the transition period from             to             
    Commission file number 001-38848
    __________________________________________
     
     
    A.Full title of the plan and the address of the plan if different from that of the issuer named below:
    STERIS Corporation 401(k) Plan

    5960 Heisley Road, Mentor, Ohio 44060-1834

     
    B.Name of issuer of securities held pursuant to the plan and the address of its principal executive office:
    STERIS plc
    70 Sir John Rogerson's Quay, Dublin 2, Ireland







    STERIS Corporation 401(k) Plan
    Financial Statements and Supplemental Schedules
    December 31, 2024 and 2023
    Contents

    Report of Independent Registered Public Accounting Firm
    3
    Financial Statements: 
    Statements of Net Assets Available for Benefits as of December 31, 2024 and 2023
    4
    Statements of Changes in Net Assets Available for Benefits for the years ended December 31, 2024 and 2023
    5
    Notes to Financial Statements
    6
    Supplemental Schedules: 
    Schedule H, Line 4i – Schedule of Assets (Held at End of Year)
    12
    Signature
    13
    Exhibit Index
    14




    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

    To the Plan Participants and Plan Administrator
    STERIS Corporation 401(k) Plan
    Mentor, Ohio


    Opinion on the Financial Statements

    We have audited the accompanying Statements of Net Assets Available for Benefits of the STERIS Corporation 401(k) Plan (the “Plan”) as of December 31, 2024 and 2023 and the related Statements of Changes in Net Assets Available for Benefits for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Information

    The supplemental information in the accompanying Schedule of Assets (Held at End of Year) as of December 31, 2024 has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

    We have served as the Plan’s auditor since 2018.

    /s/ BOBER, MARKEY, FEDOROVICH & COMPANY


    Cleveland, Ohio
    June 25, 2025






    3



    STERIS Corporation
    401(k) Plan
    Statements of Net Assets Available for Benefits
     
    December 31,
     20242023
    Assets:  
    Investments, at fair value$1,242,861,811 $1,111,564,978 
    Notes receivable from participants17,176,868 15,855,280 
    Net assets available for benefits$1,260,038,679 $1,127,420,258 
    See accompanying notes to the financial statements.
    4


    STERIS Corporation
    401(k) Plan
    Statements of Changes in Net Assets Available for Benefits
     
    Year Ended December 31,
     20242023
    Additions: 
    Investment income:
        Investment interest and dividend income$13,266,668 $12,665,131 
    Interest on notes receivable from participants1,243,262 904,840 
    Contributions: 
        Participant76,604,132 70,442,197 
        Employer29,483,123 26,958,570 
        Rollovers19,346,162 9,050,987 
             Total contributions125,433,417 106,451,754 
    Total additions139,943,347 120,021,725 
      
    Deductions: 
    Benefit payments131,600,843 80,228,982 
    Administrative expenses731,546 622,556 
    Total deductions132,332,389 80,851,538 
      
    Net unrealized and realized appreciation in the fair value of investments124,680,837 158,495,162 
    Net increase in net assets available for benefits prior to transfer132,291,795 197,665,349 
    Net transfer of assets from other plan326,626 5,265 
    Net increase in net assets available for benefits132,618,421 197,670,614 
    Net assets available for benefits at: 
    Beginning of year1,127,420,258 929,749,644 
    End of year$1,260,038,679 $1,127,420,258 
    See accompanying notes to the financial statements.

    5

    STERIS Corporation
    401(k) Plan
    Notes to Financial Statements
    December 31, 2024 and 2023


    1. Plan Description
    The following brief description of the STERIS Corporation 401(k) Plan (the “Plan”) provides only general information. A complete description of the Plan provisions, including those relating to participation, vesting and benefits, is contained in the Plan document. Participants should refer to the Plan document for complete information regarding the Plan’s provisions.
    General
    The Plan is a defined contribution plan administered by STERIS Corporation (the “Company,” or “Plan Administrator”), an indirect wholly-owned subsidiary of STERIS plc (“STERIS”).
    Generally, all U.S. employees of the Company and certain participating subsidiaries and other affiliates who have attained the age of 18 and have completed 90 days of employment with the Company or a participating subsidiary or other affiliate are eligible to participate in the Plan on the first day of the payroll period that begins after satisfying these requirements. Rehired employees who were previously participants are eligible for participation immediately upon rehire. Effective December 17, 2023, U.S. employees that joined the Company from our acquisition of assets from Becton, Dickinson and Company became eligible to participate in the Plan. The Plan contains an automatic enrollment feature for newly eligible participants and a Qualified Automatic Contribution Arrangement (QACA). The Plan contains provisions providing that an employee of the Company or a subsidiary or other affiliate who is not eligible to participate in the Plan and who is transferred to an employment status that makes him/her eligible to participate, will become a participant as of the date of transfer provided that he/she has satisfied the minimum age and service requirements at that time. The Plan was amended and restated in its entirety effective January 1, 2015, to consolidate all prior amendments into one document and to meet then applicable IRS qualification requirements that plan sponsors restate their plan documents.
    The Plan is a stock bonus plan. The portion of the Plan fund that holds investments consisting of STERIS plc ordinary shares (the “STERIS Company Stock Fund”) is an employee stock ownership plan within the meaning of Section 4975(e)(7) of the Internal Revenue Code (the “Code”). The Plan provides for a cash payment option with respect to dividends paid on STERIS shares held in the STERIS Company Stock Fund. The Plan also contains a cash or deferred arrangement intended to qualify under Section 401(k) of the Code. The Plan is qualified under Section 401(a) of the Code.
    The 401(k) Plan Oversight Committee is responsible for the general administration of the Plan. Vanguard Fiduciary Trust Company is the Plan trustee and The Vanguard Group, Inc. is the Plan record-keeper (collectively “the Trustee”). The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 as amended (“ERISA”).
    Contributions
    Contributions made by a participant are “before-tax” deferred compensation contributions or may be designated by the participant as “after-tax” Roth 401(k) contributions.
    The Plan allows participants to contribute between one and fifty percent of their compensation received during a calendar year, subject to certain limitations. The contributions for each participant are made by payroll deductions and are determined each pay period by multiplying the participant selected deferral percentage rate then in effect by his/her eligible compensation for such period.
    The Plan contains a feature that allows participants to modify deferral percentages at any time.
    The Company makes matching cash contributions to participants' accounts. The matching contributions are a percentage of the contributions made by each participant. For the years ended December 31, 2024 and 2023 employer matching contributions were 100% of a participant's contribution (not in excess of one percent of eligible compensation), and 50% of the participant's contributions (in excess of one percent but not in excess of six percent of eligible compensation), subject to certain Plan limitations. Starting in 2025, the plan is operating under employer matching contributions of 100% of a participant's contribution (not in excess of two percent of eligible compensation), and 50% of the participant's contributions (in excess of two percent but not in excess of six percent of eligible compensation). The Plan is expected to be formally amended by December 31, 2025. The employer matching contributions are made each pay period. The Company has reserved the right to amend the Plan, which includes the right to suspend, modify or terminate employer matching contributions.
    The Company also may make corrective qualified nonelective contributions to the Plan on behalf of participants.
    The Plan also allows a participant to contribute into the Plan balances from another qualified benefit plan (known as “rollover contributions”).
    6

    STERIS Corporation
    401(k) Plan
    Notes to Financial Statements (continued)
    December 31, 2024 and 2023

    Participant Accounts
    A separate account is maintained for each participant in the Plan, reflecting contributions, investments, realized and unrealized investment gains and losses, loans and interest, withdrawals, rollovers and certain fees. The net value of each participant account is established at the close of each business day through the valuation of each fund’s assets.
    Participants may elect to invest contributions, including employer contributions, in any combination of the investment funds offered by the Plan, including the STERIS Company Stock Fund. If a participant does not make an investment election with respect to 100% of the contributions made on behalf of the participant, those contributions for which no election has been made will be invested in the default investment option (Vanguard Target Retirement Date Funds), until an affirmative election of other investment options is received from the participant.
    Participants can generally change their investment elections at any time, subject to certain limitations with respect to the STERIS Company Stock Fund. A participant may elect to have a portion or all of the balance of prior contributions together with earnings transferred from the fund in which it is invested to any other fund, subject to any transfer restrictions that the fund may impose. The STERIS Company Stock Fund will not accept transfers from other investment funds or rollover contributions. A self-directed mutual fund brokerage window option also is available to participants. This option enables participants to invest in a wide variety of mutual funds, beyond the core investment funds available to all Plan participants. Participants who elect this option are subject to additional charges; these additional charges are the responsibility of the electing participants.
    Vesting
    All participants are immediately vested in their contributions and employer matching contributions plus actual earnings thereon.
    Forfeitures
    All contributions to the Plan are 100% vested; however, if for any reason an amount is required to be forfeited pursuant to Article VII of the Plan or to a correction under the Internal Revenue Service's Employee Plans Compliance Resolution System (EPCRS) program for which the Employer and the Plan are eligible, as set forth in Revenue Procedure 2013-12 or any successor thereto, such forfeiture shall be used as soon as practicable to pay Plan expenses or to reduce any Employer Contributions to be made in the Plan Year in which the forfeiture occurs or the next following Plan Year.
    Plan Withdrawals and Distributions
    Upon separation from service with the Company due to death, disability, retirement, or termination, a participant may elect to receive a lump-sum distribution equal to his or her vested account balance. To the extent that a participant's separate account is invested in the STERIS Company Stock Fund, a participant may elect to receive payment of benefits in the form of an in-kind distribution of shares held in the STERIS Company Stock Fund.
    In-service withdrawals are available in certain limited circumstances, as defined by the Plan. Hardship withdrawals are allowed for participants incurring an immediate and heavy financial need, as defined by the Plan. Hardship withdrawals are strictly regulated by Internal Revenue Service (IRS) requirements.
    Participants Loans
    Participants currently employed may borrow from their fund accounts a minimum of $1,000 up to a maximum equal to the lesser of $50,000 or 50 percent of their vested account balance. Loan terms generally range from 1-5 years and are secured by the balance in the participant’s account. Loan terms for loans used for the purchase of a participant’s primary residence can be longer than five years. The loans bear interest at a rate established by the Trustee. Principal and interest is paid through payroll deductions. Participants may have only one loan outstanding at any time and participants may take only one loan in a twelve-month period. If any amount that was not paid when due remains unpaid by the end of the calendar quarter following the quarter in which the payment was due the loan will be in default. If a participant terminates employment with the Company, they may continue to make loan payments directly to the Trustee through a pre-authorized check agreement. If the loan is not repaid, it will automatically be treated as a distribution to the participant as soon as practicable following the default.
    7

    STERIS Corporation
    401(k) Plan
    Notes to Financial Statements (continued)
    December 31, 2024 and 2023

    STERIS Company Stock Fund
    Each participant who has an investment in the STERIS Company Stock Fund holds stock fund units. These units represent a proportionate number of STERIS shares held in the STERIS Company Stock Fund. The Company Stock Fund may hold cash or other short-term securities, although these are expected to be a small percentage of the fund. The Company has implemented a dividend pass-through election for its participants for cash dividends that equal or exceed $25. Each participant is entitled to exercise voting rights attributable to the STERIS shares that his or her stock units represent. At least thirty days prior to the time such rights are to be exercised, each participant is sent, electronically or by regular mail, a copy of the proxy solicitation materials. Participants are requested to instruct the Trustee as to how shares should be voted. If a participant does not provide the Trustee with instructions as to how shares should be voted, then such shares are voted, as provided in the Plan, proportionately in accordance with the instructions received from other participants in the Plan who are voting.
    Plan Termination
    The Company, by action of its Board of Directors or Compensation and Organization Development Committee and without approval of its shareholders, has the right under the Plan to amend, suspend, or terminate the Plan in its entirety subject to the provisions of ERISA. The 401(k) Plan Oversight Committee for the Plan also is authorized to make certain Plan amendments.
    In the event of Plan termination, participants will remain 100 percent vested in their accounts.
    Administrative Expenses
    Costs incident to the purchase and sale of securities, such as brokerage commissions and stock transfer taxes, are paid by the respective funds. All other administrative expenses incurred in the administration of the Plan are charged against the respective funds, unless the Company elects to pay such amounts. A quarterly amount of $8.50 was deducted from each participant account for calendar years 2024 and 2023, to pay administrative fees. The Company has elected to pay audit, legal, and consulting fees only. Expenses that are paid by the Company are excluded from these financial statements.
    2. Summary of Accounting Policies
    Basis of Accounting
    The financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Plan financial statements have been prepared on the accrual basis of accounting. The following is a summary of the significant accounting policies followed by the Plan in the preparation of its financial statements.
    Investment Valuation and Income Recognition
    Investments held by the Plan are stated at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). See Note 5 for further discussion and disclosures related to fair value measurements.
    Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net appreciation (depreciation) includes the Plan's gains and losses on investments bought and sold as well as held during the year.
    Use of Estimates
    The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and supplemental schedules. Actual results could differ from those estimates.
    Notes Receivable from Participants
    Notes receivable from participants are measured at amortized cost, which represents the unpaid principal balance plus any accrued but unpaid interest. Interest income on notes receivable from participants is recorded when earned. Related fees are recorded as administrative expenses and are recorded when incurred. If a participant ceases to make loan repayments and the plan administrator deems the participant loan to be a distribution, the participant loan balance is reduced and a benefit payment is recorded. No allowance for credit losses has been recorded as of December 31, 2024 and 2023.
    Payment of Benefits
    Benefits are recorded when paid.
    8

    STERIS Corporation
    401(k) Plan
    Notes to Financial Statements (continued)
    December 31, 2024 and 2023

    Subsequent Events
    Plan management evaluates subsequent events through the financial statement issuance date.
    3. Transactions with Parties-in-Interest
    Party-in-interest transactions include the investment in the funds of the Trustee and funds maintained by entities affiliated with the Trustee and the payment of administrative expenses. Permissible Plan loans to participants are also party-in-interest transactions. Total purchases and sales of STERIS shares transacted by funds of the Plan, along with dividends received by the Plan on such shares, are presented in the table below.
    Year Ended December 31,
    STERIS Share Activity(1)
    20242023
    Purchased$3,760,678 $3,569,288 
    Sold$15,799,109 $10,692,788 
    Dividends received$907,050 $908,327 
    (1) These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transactions rules under ERISA.
    4. Tax Status
    The Plan received a determination letter from the Internal Revenue Service dated October 9, 2015, stating that the Plan is qualified under Section 401(a) of the Code. This determination also meant, in effect, that the related trust was determined to be exempt from taxation. The Plan is required to operate in conformity with the Code to maintain its qualified status. The Plan Administrator has indicated that it will take the necessary steps, if any, to bring the Plan's operations into compliance with the Code requirements in the event of any noncompliance.
    U.S. GAAP requires the Company to evaluate tax positions taken by the Plan and recognize a tax asset or liability if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. The Company has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2024, there are no uncertain positions taken or expected to be taken. The Plan is subject to routine audits by the Internal Revenue Service; however, there are currently no tax audits for any tax periods in respect of the Plan in progress.
    5. Fair Value Measurements
    Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Investments are classified in a hierarchy based on the inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The three levels of the fair value hierarchy are described below:
    Level 1 - Unadjusted quoted prices for identical assets or liabilities in active markets.
    Level 2 - Inputs to the valuation methodology include, quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in inactive markets; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.
    Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement. These inputs reflect management's judgment about the assumptions that a market participant would use in pricing the investment and are based on the best available information, some of which may be internally developed.
    9

    STERIS Corporation
    401(k) Plan
    Notes to Financial Statements (continued)
    December 31, 2024 and 2023

    The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement.
    The following describes the valuation techniques used for assets measured at fair value.
    Mutual funds: Valued at the price reported by the fund. Mutual funds held by the Plan have publicly available prices and are registered with the Securities and Exchange Commission. Money market fund holdings are valued and transacted at a net asset value (“NAV”). NAV is computed by dividing the total assets, minus liabilities, of the fund by the number of fund shares outstanding. The instruments held by a money market fund generally are valued on the basis of amortized cost, which does not take into account unrealized capital gains or losses.
    STERIS Company Stock Fund: Valued based on the year end unit value; unit values were determined by the Trustee by dividing the fair values of the total net assets at year end by the outstanding units.
    Collective Trusts: Valued at the NAV on the last business day of the Plan’s year end, which is provided by the Trustee of the fund and used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, divided by the number of units outstanding. Since these investments are measured at fair value using the NAV as a practical expedient, they are not classified in the fair value hierarchy.
    The following tables set forth by level, within the fair value hierarchy, the Plan’s assets measured at fair value on a recurring basis as of December 31, 2024 and 2023:
    TotalLevel 1Level 2Level 3
    December 31, 2024   
    Cash$1,436,271 $1,436,271 $— $— 
    STERIS Company Stock Fund81,552,897 81,552,897 — — 
    Mutual Funds467,543,520 419,161,873 48,381,647 — 
    Total assets in fair value hierarchy$550,532,688 $502,151,041 $48,381,647 $— 
    Collective Trusts (1)
    692,329,123 — — — 
    Total assets at fair value$1,242,861,811 $502,151,041 $48,381,647 $— 
    (1) In accordance with Subtopic 820-10 of ASC 820 Fair Value Measurement, certain investments that were measured at net asset value per share as a practical expedient are not required to be classified in the fair value hierarchy. The fair value amounts are intended to permit reconciliation of the fair value hierarchy to the line item in the Statements of Net Assets Available for Benefits.
    TotalLevel 1Level 2Level 3
    December 31, 2023   
    Cash$1,316,498 $1,316,498 $— $— 
    STERIS Company Stock Fund97,993,351 97,993,351 — — 
    Mutual Funds415,034,206 359,768,587 55,265,619 — 
    Total assets in fair value hierarchy$514,344,055 $459,078,436 $55,265,619 $— 
    Collective Trusts (1)
    597,220,923 — — — 
    Total assets at fair value$1,111,564,978 $459,078,436 $55,265,619 $— 
    (1) In accordance with Subtopic 820-10 of ASC 820 Fair Value Measurement, certain investments that were measured at net asset value per share as a practical expedient are not required to be classified in the fair value hierarchy. The fair value amounts are intended to permit reconciliation of the fair value hierarchy to the line item in the Statements of Net Assets Available for Benefits.
    Plan investments measured at net asset value per share and excluded from the fair value hierarchy are collective funds in the amount of $692,329,123 and $597,220,923 at December 31, 2024 and 2023, respectively. These Plan investments can be redeemed daily, however, are subject to the Plan's frequent trading policy which states if a fund is sold or exchanged, it is not permitted to buy or exchange back into the same fund, in the same account, within 30 calendar days. Redemption of the entire investment balance does not require formal notice unless the balance is greater than Vanguard's Large Transaction Policy limit for the given fund. If the redemption amount exceeds the fund's limit, Vanguard must be notified and approve the redemption. At December 31, 2024 and 2023, the Plan had no unfunded commitments related to these investments.
    10

    STERIS Corporation
    401(k) Plan
    Notes to Financial Statements (continued)
    December 31, 2024 and 2023

    6. Risks and Uncertainties
    The Plan invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants’ account balances and the amounts reported in the statements of net assets available for benefits.
    Participants are responsible for researching and judging for themselves the suitability of any particular security, transaction or investment strategy and the associated inherent risk of loss.
    11


    STERIS Corporation
    401(k) Plan
    EIN:  34-1482024           
    Plan Number:  001
    Schedule H, Line 4i—Schedule of Assets
    (Held at End of Year)
    December 31, 2024

    Identity of Issuer, Borrower,
    Lessor, or Similar Party
    Description of Investment
    Including Maturity Date,
    Rate of Interest, Collateral,
    Par, or Maturity Value
    CostCurrent Value
    Cash:
    * Vanguard brokerage option - cash1,436,271 Units**$1,436,271 
    Stock:   
    * STERIS plcSTERIS Company Stock Fund - 407,357Units**81,552,897 
        
    Mutual Funds:   
    * Vanguard Extended Market Index Fund: Institutional Plus Shares269,300 Shares**95,749,657 
    * Vanguard FTSE All-World ex-US Index Fund: Institutional Shares293,718 Shares**33,210,714 
    * Vanguard Federal Money Market Fund47,397,014 Shares**47,397,014 
    * Vanguard Institutional Index Fund Institutional Plus Shares
    491,525 Shares**235,381,440 
    * Vanguard Total Bond Market Index Fund Institutional Shares4,284,677 Shares**40,618,740 
    * Vanguard brokerage optionVarious registered investment companies**15,185,955 
    467,543,520 
    Collective Trusts:
    * Vanguard Target Retirement 2020 Trust I306,736 Shares**23,198,445 
    * Vanguard Target Retirement 2025 Trust I910,680 Shares**73,072,992 
    * Vanguard Target Retirement 2030 Trust I1,180,057 Shares**99,301,800 
    * Vanguard Target Retirement 2035 Trust I1,224,496 Shares**109,457,678 
    * Vanguard Target Retirement 2040 Trust I1,035,959 Shares**99,203,437 
    * Vanguard Target Retirement 2045 Trust I965,749 Shares**96,333,444 
    * Vanguard Target Retirement 2050 Trust I824,990 Shares**84,041,725 
    * Vanguard Target Retirement 2055 Trust I451,558 Shares**56,083,529 
    * Vanguard Target Retirement 2060 Trust I450,092 Shares**29,377,491 
    * Vanguard Target Retirement 2065 Trust I234,763 Shares**9,425,717 
    * Vanguard Target Retirement 2070 Trust I55,393 Shares**1,356,018 
    * Vanguard Target Retirement Income Trust I168,852 Shares**11,476,847 
       692,329,123 
    Other:   
    * Participant LoansBearing interest between 4.25% and 9.50% and maturing through 2034-17,176,868 
       $1,260,038,679 
    * Indicated party-in-interest to the Plan.
    ** Participant-directed investment, cost not required

    12


    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Administrator of the Plan has duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.
      STERIS Corporation 401(k) Plan
        
      By:STERIS Corporation
       Plan Administrator
        
    Dated:June 25, 2025By:/s/ Karen L. Burton
       Karen L. Burton
       Vice President, Chief Accounting Officer
        

    13


    EXHIBIT INDEX

    Exhibit
    Number
    Exhibit Description
    23.1
    Consent of Independent Registered Public Accounting Firm
    14
    Get the next $STE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    5/29/2025$263.00Hold
    Jefferies
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    4/7/2022$275.00Outperform
    Wolfe Research
    More analyst ratings

    $STE
    SEC Filings

    See more
    • SEC Form DEFA14A filed by STERIS plc (Ireland)

      DEFA14A - STERIS plc (0001757898) (Filer)

      7/3/25 4:32:12 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by STERIS plc (Ireland)

      8-K - STERIS plc (0001757898) (Filer)

      7/3/25 4:30:29 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form 11-K filed by STERIS plc (Ireland)

      11-K - STERIS plc (0001757898) (Filer)

      6/25/25 4:16:24 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Leadership Updates

    Live Leadership Updates

    See more
    • STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

      DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

      5/3/23 4:30:00 PM ET
      $CDMO
      $STE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • STERIS Announces Changes to Board of Directors

      David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W

      5/11/21 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Steris with a new price target

      Jefferies initiated coverage of Steris with a rating of Hold and set a new price target of $263.00

      5/29/25 8:18:41 AM ET
      $STE
      Industrial Specialties
      Health Care
    • Steris upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

      10/24/24 6:28:31 AM ET
      $STE
      Industrial Specialties
      Health Care
    • KeyBanc Capital Markets resumed coverage on Steris with a new price target

      KeyBanc Capital Markets resumed coverage of Steris with a rating of Overweight and set a new price target of $253.00

      2/6/24 6:38:21 AM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP, Gen Counsel, and Sec. Zangerle John Adam sold $477,581 worth of Ordinary Shares (1,978 units at $241.45), decreasing direct ownership by 6% to 33,760 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      6/17/25 4:34:39 PM ET
      $STE
      Industrial Specialties
      Health Care
    • Sr. Vice Pres., CFO Tokich Michael J covered exercise/tax liability with 341 units of Ordinary Shares, decreasing direct ownership by 0.77% to 43,891 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      6/6/25 4:35:34 PM ET
      $STE
      Industrial Specialties
      Health Care
    • Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 194 units of Ordinary Shares, decreasing direct ownership by 2% to 10,762 units (SEC Form 4)

      4 - STERIS plc (0001757898) (Issuer)

      6/6/25 4:34:53 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Financials

    Live finance-specific insights

    See more
    • STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year

      Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

      5/14/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS Declares Dividend of $0.57 per share

      DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on June 26, 2025, to shareholders of record at the close of business on June 10, 2025.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and se

      5/7/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care
    • STERIS to Host a Conference Call for Fiscal 2025 Fourth Quarter and Full Year Financial Results on May 15, 2025

      DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

      4/22/25 4:30:00 PM ET
      $STE
      Industrial Specialties
      Health Care

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/13/24 5:14:05 PM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:49:03 AM ET
      $STE
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

      SC 13G/A - STERIS plc (0001757898) (Subject)

      2/9/24 11:32:52 AM ET
      $STE
      Industrial Specialties
      Health Care